See more : BCE Inc. (BCEPF) Income Statement Analysis – Financial Results
Complete financial analysis of IMAC Holdings, Inc. (IMAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IMAC Holdings, Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- GRID Inc. (5582.T) Income Statement Analysis – Financial Results
- Greene Concepts, Inc. (INKW) Income Statement Analysis – Financial Results
- Founder Group Limited Ordinary Shares (FGL) Income Statement Analysis – Financial Results
- MITSUI-SOKO HOLDINGS Co., Ltd. (9302.T) Income Statement Analysis – Financial Results
- Maggie Beer Holdings Limited (MBH.AX) Income Statement Analysis – Financial Results
IMAC Holdings, Inc. (IMAC)
About IMAC Holdings, Inc.
IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.20M | 16.19M | 14.39M | 12.84M | 15.13M | 6.70M | 786.03K | 15.00K |
| Cost of Revenue | 1.35M | 1.51M | 1.63M | 1.62M | 2.54M | 933.91K | 63.22K | 4.27K |
| Gross Profit | 3.85M | 14.68M | 12.76M | 11.21M | 12.59M | 5.77M | 722.81K | 10.73K |
| Gross Profit Ratio | 74.05% | 90.68% | 88.68% | 87.35% | 83.21% | 86.06% | 91.96% | 71.56% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | -6.26K | 21.80M | 19.73M | 15.44M | 15.98M | 7.81M | 1.45M | 204.78K |
| Selling & Marketing | 7.73K | 1.10M | 1.32M | 933.34K | 1.24M | 859.19K | 119.87K | 25.00K |
| SG&A | 1.47K | 22.90M | 21.06M | 16.38M | 17.22M | 8.67M | 1.57M | 229.78K |
| Other Expenses | 0.00 | 1.63M | 1.65M | 1.31M | 1.55M | 18.36K | 65.90K | 0.00 |
| Operating Expenses | 5.03M | 24.53M | 22.71M | 17.68M | 18.77M | 9.32M | 1.64M | 229.78K |
| Cost & Expenses | 6.38M | 26.03M | 24.33M | 19.31M | 21.31M | 10.25M | 1.70M | 234.05K |
| Interest Income | 0.00 | 10.58K | 2.89K | 6.07K | 7.79K | 7.54K | 14.82K | 4.00 |
| Interest Expense | 0.00 | 14.19K | 504.10K | 563.07K | 897.69K | 153.82K | 27.15K | 4.00 |
| Depreciation & Amortization | 403.59K | 1.63M | 1.65M | 1.72M | 1.55M | 651.07K | 65.90K | 219.05K |
| EBITDA | -5.95M | -10.20M | -8.39M | -3.26M | -4.50M | -2.98M | -823.48K | -397.44K |
| EBITDA Ratio | -114.43% | -50.91% | -57.28% | -36.96% | -30.68% | -44.47% | -104.42% | -2,649.60% |
| Operating Income | -6.38M | -9.85M | -9.95M | -6.47M | -6.19M | -3.55M | -915.07K | -219.05K |
| Operating Income Ratio | -122.68% | -60.85% | -69.16% | -50.43% | -40.89% | -53.00% | -116.42% | -1,460.31% |
| Total Other Income/Expenses | -99.85K | 6.11K | -443.89K | 993.86K | -765.96K | -233.48K | -1.47K | -178.39K |
| Income Before Tax | -6.48M | -18.31M | -10.54M | -5.54M | -6.95M | -3.78M | -916.53K | -397.44K |
| Income Before Tax Ratio | -124.60% | -113.14% | -73.28% | -43.18% | -45.96% | -56.48% | -116.60% | -2,649.60% |
| Income Tax Expense | 0.00 | 8.43M | 561.43K | 24.37K | 427.20K | -79.65K | -818.59K | -16.65K |
| Net Income | -9.42M | -26.74M | -11.10M | -5.57M | -7.38M | -3.05M | -57.18K | -380.80K |
| Net Income Ratio | -181.23% | -165.24% | -77.18% | -43.37% | -48.78% | -45.57% | -7.27% | -2,538.65% |
| EPS | -5.06 | -28.38 | -14.77 | -15.11 | -28.55 | -12.65 | -0.38 | -2.56 |
| EPS Diluted | -7.36 | -28.38 | -14.77 | -15.11 | -28.55 | -12.65 | -0.38 | -2.56 |
| Weighted Avg Shares Out | 1.62M | 942.46K | 751.72K | 368.34K | 258.45K | 241.43K | 150.40K | 149.02K |
| Weighted Avg Shares Out (Dil) | 1.11M | 942.46K | 751.72K | 368.34K | 258.45K | 241.43K | 150.40K | 149.02K |
IMAC Holdings, Inc. Announces Completion of First Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease
BRENTWOOD, Tenn, March 01, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), today announces it has completed the first cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal...
IMAC Holdings Adds Regenerative Wound Care Service in Regeneration Centers
Insurance to Reimburse Services Providing Cell-Based Amniotic-Infused Mesh Application to Chronic Non-Healing Wounds and Diabetic Foot Ulcers
5 Stocks to Buy Now Trading Under $10 With Mammoth Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
IMAC Holdings Celebrates One-Year Anniversary of Health Maintenance Plans Surpassing 1,000 Members and Demonstrating Increased Demand for Spinal Wellness Among Its IMAC Regeneration Center Customers
BRENTWOOD, Tenn., Jan. 21, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces...
IMAC Holdings Expands Florida Presence to Orlando Following Acquisition of Synergy Healthcare
BRENTWOOD, Tenn., Jan. 14, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces...
IMAC Stock Price Increases 23.97%: Why It Happened
The stock price of IMAC Holdings Inc (NASDAQ: IMAC) has increased by 23.53% as it went from a previous close of $1.19 to $1.47. This is why.
IMAC Holdings Completes First Infusion of Stem Cells in Clinical Study for the Treatment of Bradykinesia Due to Parkinson's Disease
BRENTWOOD, Tenn., Dec. 30, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, announces it...
IMAC Holdings Receives Forgiveness of $1.69 Million PPP Loan
BRENTWOOD, Tenn., Dec. 04, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces...
IMAC Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
BRENTWOOD, Tenn, Nov. 30, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces...
IMAC Holdings, Inc. To Participate in the Virtual Fall Investor Summit on November 16-18, 2020
BRENTWOOD, Tenn, Nov. 13, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces...
Source: https://incomestatements.info
Category: Stock Reports